NL940006I1 - 1,2-Benzisoxyzol-3-yl- en 1,2-benzisothiazol-3-yl-derivaten - Google Patents

1,2-Benzisoxyzol-3-yl- en 1,2-benzisothiazol-3-yl-derivaten

Info

Publication number
NL940006I1
NL940006I1 NL940006C NL940006C NL940006I1 NL 940006 I1 NL940006 I1 NL 940006I1 NL 940006 C NL940006 C NL 940006C NL 940006 C NL940006 C NL 940006C NL 940006 I1 NL940006 I1 NL 940006I1
Authority
NL
Netherlands
Prior art keywords
benzisoxyzol
benzisothiazol
derivatives
Prior art date
Application number
NL940006C
Other languages
English (en)
Other versions
NL940006I2 (nl
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26664247&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL940006(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NL940006I1 publication Critical patent/NL940006I1/nl
Publication of NL940006I2 publication Critical patent/NL940006I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
NL940006C 1985-03-27 1994-04-11 1,2-Benzuisoxazol-3-yl-en 1,2-benzisothiazol-3-yl-derivaten. NL940006I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71706785A 1985-03-27 1985-03-27
SG119294A SG119294G (en) 1985-03-27 1994-08-20 1,2-benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives

Publications (2)

Publication Number Publication Date
NL940006I1 true NL940006I1 (nl) 1994-05-16
NL940006I2 NL940006I2 (nl) 1999-09-01

Family

ID=26664247

Family Applications (1)

Application Number Title Priority Date Filing Date
NL940006C NL940006I2 (nl) 1985-03-27 1994-04-11 1,2-Benzuisoxazol-3-yl-en 1,2-benzisothiazol-3-yl-derivaten.

Country Status (15)

Country Link
US (1) US4804663A (nl)
EP (1) EP0196132B1 (nl)
JP (1) JPH0613511B2 (nl)
CN (1) CN1022566C (nl)
AU (1) AU579232B2 (nl)
BG (1) BG60432B2 (nl)
CA (1) CA1256867A (nl)
CY (1) CY1801A (nl)
DK (1) DK168537B1 (nl)
HK (1) HK108794A (nl)
IE (1) IE58388B1 (nl)
LU (1) LU88576I2 (nl)
NL (1) NL940006I2 (nl)
SG (1) SG119294G (nl)
SU (1) SU1468419A3 (nl)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335289C (en) * 1987-10-26 1995-04-18 Fujio Antoku Piperidinyl benzisoxazole derivatives, their production and pharmaceutical use
US5001130A (en) * 1988-02-18 1991-03-19 Bristol-Myers Company Psychotropic heterobicycloalkylpiperazine derivatives
US5116970A (en) * 1988-02-18 1992-05-26 New James S Psychotropic heterobicycloalkylpiperazine derivatives: 2. fused pyridazinones
GR1000667B (el) * 1988-03-21 1992-09-25 Janssen Pharmaceutica Nv Μεθοδος παρασκευης 3-πιπεριδινυλο-1,2-βενζισοξαζολων.
NZ230045A (en) * 1988-08-05 1990-11-27 Janssen Pharmaceutica Nv 3-piperazinylbenzazole derivatives and pharmaceutical compositions
US5015740A (en) * 1988-08-05 1991-05-14 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
US4957916A (en) * 1988-08-05 1990-09-18 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
US5196425A (en) * 1988-09-02 1993-03-23 Janssen Pharmaceutica N.V. Antihypertensive 3-piperidinyl-indazole derivatives
IL90879A0 (en) * 1988-09-02 1990-02-09 Janssen Pharmaceutica Nv 3-piperidinyl-indazole derivatives,their preparation and antihypertensive compositions containing them
US5321028A (en) * 1988-09-02 1994-06-14 Janssen Pharmaceutica N.V. Antihypertensive 3-piperidinyl-indazole derivatives
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
CA2000786C (en) * 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5153206A (en) * 1988-12-02 1992-10-06 Pfizer Inc. Arylpiperidine derivatives
FR2641278B1 (fr) * 1989-01-05 1991-03-22 Lipha Piperidines, procedes de preparation et medicaments les contenant
US5256659A (en) * 1989-01-09 1993-10-26 Janssen Pharmaceutica N.V. 2-aminopyrimidinone derivatives
GB8900382D0 (en) * 1989-01-09 1989-03-08 Janssen Pharmaceutica Nv 2-aminopyrimidinone derivatives
FR2654104B1 (fr) * 1989-11-07 1992-01-03 Adir Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
FR2671350A1 (fr) * 1991-01-08 1992-07-10 Adir Nouveaux derives de benzisoxazole et de benzisothiazole, leur procede de preparation, et les compositions pharmaceutiques les renfermant.
GB9008850D0 (en) * 1990-04-19 1990-06-13 Janssen Pharmaceutica Nv Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones
US5075315A (en) * 1990-05-17 1991-12-24 Mcneilab, Inc. Antipsychotic hexahydro-2H-indeno[1,2-c]pyridine derivatives
US6004980A (en) * 1990-06-01 1999-12-21 Merrell Pharmaceuticals, Inc. (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
DK0531410T3 (da) * 1990-06-01 1995-01-30 Merrell Dow Pharma (+)-alfa-(2,3-Demethoxyphenyl)-1-(2-(4-fluorphenyl)ethyl)-4-piperidinmethanol
US5147881A (en) * 1990-11-14 1992-09-15 Pfizer Inc 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents
WO1993004063A1 (en) * 1991-08-22 1993-03-04 Yoshitomi Pharmaceutical Industries, Ltd. Benzisoxazole compound and use thereof
AU655071B2 (en) * 1991-09-25 1994-12-01 Pfizer Inc. Neuroleptic 2-substituted perhydro-1-H-pyrido(1,2a) pyrazines
US5532243A (en) * 1992-02-14 1996-07-02 The Dupont Merck Pharmaceutical Company Antipsychotic nitrogen-containing bicyclic compounds
DE4243287A1 (de) * 1992-06-19 1993-12-23 Basf Ag N-Substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung
JPH07508741A (ja) 1992-07-13 1995-09-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 新規４−（３−ベンゾフラニル）ピペリジニル及び４−（３−ベンゾチエニル）ピペリジニル誘導体，ならびにそれらを含む製薬学的組成物
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
DE4338396A1 (de) * 1993-11-10 1995-05-11 Basf Ag N-Substituierte Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
WO1995013814A1 (en) * 1993-11-19 1995-05-26 Janssen Pharmaceutica N.V. Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
JP3553951B2 (ja) * 1993-11-23 2004-08-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 新規な９−ヒドロキシ−ピリド［１，２−ａ］ピリミジン−４−オンエーテル誘導体
ES2074966B1 (es) * 1994-02-11 1996-06-16 Vita Invest Sa Procedimiento para la obtencion de 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il)piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a)pirimidin-4-ona.
ES2085234B1 (es) * 1994-02-24 1997-01-16 Vita Invest Sa Agente activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
CA2144669A1 (en) 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
EP0794185A4 (en) * 1994-11-25 1998-03-25 Meiji Seika Co BICYCLIC THIAZOLE COMPOUND
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
HUP9800631A3 (en) 1995-02-28 1998-12-28 Lundbeck & Co As H 4-aminotetrahydrobenzisoxazole or -isothiazole derivatives, pharmaceutical compositions containing them and their use for the preparation of pharmaceutical compositions
TW592729B (en) * 1995-04-06 2004-06-21 Janssen Pharmaceutica Nv Rate-controlled transdermal administration of risperidone
KR960042947A (ko) * 1995-05-09 1996-12-21 김주용 고집적 반도체 소자 및 그 국부 연결 방법
ES2097093B1 (es) * 1995-05-26 1998-01-16 Ferrer Int Nuevos compuestos derivados de 5h-tiazolo (3,2-a) pirimidin-5-ona.
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
ES2141671B1 (es) * 1997-12-26 2001-01-01 Vita Invest Sa Compuesto pirimidinico activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
AU2000255635A1 (en) 2000-05-05 2001-11-20 Rpg Life Sciences Limited A process for the preparation of anti-pschotic 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl -6,7,8,9-tetrahydro-2-methyl-4h-pyridol(1,2,-a)pyrimidin-4- one
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AU2001284763A1 (en) * 2000-08-08 2002-02-18 Teva Pharmaceutical Industries Ltd. Preparation of risperidone
MXPA03001337A (es) * 2000-08-14 2005-06-30 Teva Pharma Preparacion de risperidona.
EP1783118B1 (en) * 2000-08-14 2008-07-16 Teva Pharmaceutical Industries Ltd. Preparation of risperidone
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
DE10129320A1 (de) 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US6730772B2 (en) 2001-06-22 2004-05-04 Venkatram P. Shastri Degradable polymers from derivatized ring-opened epoxides
ES2370634T3 (es) * 2001-08-31 2011-12-21 Novartis Ag Isómeros ópticos de un metabolito de iloperidona.
HU227118B1 (en) * 2001-11-13 2010-07-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of 3-{2-[4-(6-fluoro-1,2-benzizoxazol-3-yl)-1-piperidinyl]-ethyl}-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one
WO2003054226A2 (en) * 2001-12-10 2003-07-03 Novartis Ag Methods of treating psychosis and schizophrenia based on a polymorphism in the ctf gene
ES2197801B1 (es) 2002-03-05 2005-03-16 Ferrer Internacional,S.A Procedimiento de obtencion de la 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il) piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a ) pirimidin-4-ona.
WO2004009591A1 (en) * 2002-07-22 2004-01-29 Aurobindo Pharma Ltd. A process for the preparation of antipsychotic risperidone
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
WO2004017975A1 (en) * 2002-08-23 2004-03-04 Ranbaxy Laboratories Limited Stable aqueous solutions of risperidone and methods for their preparation
WO2004020439A2 (en) * 2002-08-30 2004-03-11 Sunil Sadanand Nadkarni Improved process for preparation of risperidone
KR20040025224A (ko) * 2002-09-18 2004-03-24 주식회사 대웅 2-(2-메틸-4-옥소-6,7,8,9-테트라하이드로-4Ｈ-피리도[1,2-ａ]피리미딘-3-일)아세트알데히드 및 그 제조방법
US6800663B2 (en) * 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
KR20040034996A (ko) * 2002-10-18 2004-04-29 한미약품 주식회사 리스페리돈의 개선된 제조방법
WO2004043923A1 (en) * 2002-11-13 2004-05-27 Synthon B.V. Process for making risperidone and intermediates therefor
DE10259382A1 (de) * 2002-12-18 2004-07-01 Abbott Gmbh & Co. Kg 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-4-on-Derivate, ihre Herstellung und Verwendung
US7658998B2 (en) * 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
WO2004094415A1 (en) * 2003-04-22 2004-11-04 Synthon B.V. Risperidone monohydrochloride
MXPA05012317A (es) * 2003-05-16 2006-01-30 Pfizer Prod Inc Combinaciones terapeuticas de agentes antipsicoticos atipicos con agentes moduladores del gaba anticonvulsivos o benzodiazepinas.
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
US20070179163A1 (en) * 2003-09-26 2007-08-02 Rao Guntu S Process for the preparation of risperidone
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
UA82561C2 (uk) 2003-10-23 2008-04-25 Оцука Фармасьютикалз Ко., Лтд. Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
EP1689721B1 (en) * 2003-11-26 2010-07-14 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
BRPI0510942A (pt) * 2004-05-11 2007-07-17 Pfizer Prod Inc combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US20060004199A1 (en) * 2004-07-01 2006-01-05 Dr. Reddy's Laboratories Limited Process for the preparation of pure 3-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
AU2005277134A1 (en) * 2004-08-24 2006-03-02 Janssen Pharmaceutica N.V. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
ES2317138T3 (es) * 2004-11-22 2009-04-16 Hisamitsu Pharmaceutical Co., Inc. Parche transdermico que comprende un agente de diminucion del punto de fusion.
CA2601509A1 (en) * 2005-03-18 2006-09-28 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions
BRPI0610028A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp combinações terapêuticas para o tratamento ou a prevenção de distúrbios psicóticos
BRPI0610864A2 (pt) * 2005-05-20 2010-08-03 Janssen Pharmaceutica Nv processo para preparação de derivados de sulfamida
WO2006129160A2 (en) * 2005-06-01 2006-12-07 Aurobindo Pharma Limited Stable aqueous oral solution of risperidone
JP2009508859A (ja) * 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
US20070134310A1 (en) * 2005-09-23 2007-06-14 Nedberge Diane E Transdermal risperidone delivery system
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
GB0603087D0 (en) * 2006-02-15 2006-03-29 Glaxo Group Ltd Novel use
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
JP4922657B2 (ja) * 2006-05-09 2012-04-25 高田製薬株式会社 リスペリドン経口用液剤
JP2009537635A (ja) * 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
KR20090029200A (ko) * 2006-05-22 2009-03-20 반다 파마슈티칼즈, 인코퍼레이티드. 우울증 질환에 대한 치료
EP2041304B1 (en) 2006-06-12 2011-09-07 Hadasit Medical Research Services & Development Limited Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
JP2009512627A (ja) * 2006-08-14 2009-03-26 テバ ファーマシューティカル インダストリーズ リミティド ９−ヒドロキシリスペリドン（パリペリドン）の合成方法
WO2008047340A1 (en) * 2006-10-19 2008-04-24 Mor Research Applications Ltd. Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders
WO2008066750A1 (en) 2006-11-22 2008-06-05 Seaside Therapeutics, Llc Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism
WO2008087557A2 (en) * 2007-01-08 2008-07-24 Actavis Group Ptc Ehf An improved process for preparation of 9-hydroxy-3-(2-chloroethyl)- 2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one hydrochloride
CN101245065B (zh) * 2007-02-14 2010-05-19 江苏恩华药业股份有限公司 制备苯并异噁唑衍生物的方法及其中间体
JP4941977B2 (ja) * 2007-04-11 2012-05-30 大蔵製薬株式会社 ベンズイソキサゾール誘導体の経口ゼリー状医薬組成物
US10010612B2 (en) 2007-05-25 2018-07-03 Indivior Uk Limited Sustained delivery formulations of risperidone compounds
MY152789A (en) * 2007-07-31 2014-11-28 Otsuka Pharma Co Ltd Methods for producing aripiprazole suspension and freeze-dried formulation
US20090061005A1 (en) * 2007-08-21 2009-03-05 Actavis Group Ptc Ehf Paliperidone Polymorphs
US20090087487A1 (en) * 2007-08-21 2009-04-02 Michael Fox Paliperidone sustained release formulation
US7776866B2 (en) * 2007-09-15 2010-08-17 Protia, Llc Deuterium-enriched risperidone
CL2008003667A1 (es) 2007-12-10 2010-06-04 Synthon Bv Proceso de preparacion de etil-6,7,8,9-tetrahidro-9-hidroxi-2-metil-4h-pirido[1,2-a]piridin-4-ona; y uno de los intermediarios considerados en el proceso descrito; util en la preparacion de paliperidona.
DK2234617T3 (da) * 2007-12-19 2021-05-25 Janssen Pharmaceutica Nv Doseringsskema forbundet med langtidsvirkende injicerbare paliperidonestere
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
EP2280967A2 (en) * 2008-03-27 2011-02-09 Actavis Group PTC EHF Highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
EP2300467A4 (en) * 2008-06-16 2012-04-25 Msn Lab Ltd NEW AND IMPROVED METHODS FOR THE MANUFACTURE OF PALIPERIDONE
WO2010008776A2 (en) 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Disposable patch and reusable sensor assembly for use in medical device localization and mapping systems
EP2321011A1 (en) * 2008-06-25 2011-05-18 Pfizer Inc. Diaryl compounds and uses thereof
EP2138498A1 (en) * 2008-06-26 2009-12-30 sanofi-aventis Substituted tricyclic derivatives against neurodegenerative diseases
EP2138495A1 (en) * 2008-06-26 2009-12-30 sanofi-aventis Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives
EP2138488A1 (en) * 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
EP2138485A1 (en) * 2008-06-26 2009-12-30 sanofi-aventis Substituted N-Oxide pyrazine derivatives
EP2138492A1 (en) * 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidin-4-one derivatives
EP2138493A1 (en) * 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidone derivatives
EP2138494A1 (en) * 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives
WO2010003703A2 (en) 2008-07-11 2010-01-14 Synthon B.V. Paliperidone ketone
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
EP2199293A1 (en) 2008-12-22 2010-06-23 Chemo Ibérica, S.A. One-step process for preparing paliperidone and its oxalate salt
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
WO2010136895A1 (en) 2009-05-28 2010-12-02 Actavis Group Ptc Ehf Solid state forms of paliperidone salts and process for the preparation thereof
US8252801B1 (en) 2009-06-03 2012-08-28 Abbott Laboratories Treatment of schizophrenia and related disorders
EP2275423B9 (en) 2009-07-13 2012-08-15 KRKA, d.d., Novo mesto Process for the synthesis of paliperidone
WO2011030224A2 (en) 2009-09-10 2011-03-17 Actavis Group Ptc Ehf Paliperidone or a pharmaceutically acceptable salt thereof substantially free of impurities
AU2010339689B2 (en) 2010-01-07 2015-02-19 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
US9271939B2 (en) 2010-03-15 2016-03-01 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
EP2588112B1 (en) 2010-06-30 2017-09-27 Victoria Link Ltd Methods and compositions for treatment of multiple sclerosis
HUE041981T2 (hu) 2010-08-23 2019-06-28 Alkermes Pharma Ireland Ltd Eljárások antipszichotikum által kiváltott súlygyarapodás kezelésére
WO2012035554A1 (en) 2010-09-14 2012-03-22 Megafine Pharma (P) Ltd. An improved process for the preparation of highly pure paliperidone
MX346185B (es) 2010-11-15 2017-03-10 Agenebio Inc Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo.
ES2564973T3 (es) 2011-04-26 2016-03-30 Torrent Pharmaceuticals Limited Sales por adición de ácidos de risperidona y composiciones farmacéuticas de las mismas
WO2013095314A1 (en) 2011-12-19 2013-06-27 Mahmut Bilgic Pharmaceutical formulations comprising risperidone
WO2013100876A1 (en) 2011-12-27 2013-07-04 Mahmut Bilgic Risperidone formulations
WO2014031645A1 (en) * 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to risperidone haptens and use thereof
EP2888287A4 (en) 2012-08-21 2016-04-20 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE HAPTENES AND THEIR USE
CA2882560C (en) * 2012-08-21 2020-10-27 Ortho-Clinical Diagnostics, Inc. Haptens of risperidone and paliperidone for use in immunoassays
US9664700B2 (en) 2012-08-21 2017-05-30 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
AU2013305965B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Antibodies to paliperidone and use thereof
EP2900220B1 (en) * 2012-09-28 2018-12-12 Delpor, Inc. Device and methods for sustained release of antipsychotic medications
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
NZ722077A (en) 2013-12-20 2021-12-24 Agenebio Inc Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CA2965895C (en) 2014-11-07 2019-08-06 Indivior Uk Limited The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
MX2017015752A (es) 2015-06-19 2018-04-13 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo.
EP3390449A1 (en) 2015-12-17 2018-10-24 Janssen Pharmaceutica N.V. Antibodies to risperidone and use thereof
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
JP2021528427A (ja) 2018-06-19 2021-10-21 エージンバイオ， インコーポレイテッド 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4128641A (en) * 1975-07-31 1978-12-05 Hzi Research Center Inc. Tetracyclic psychotropic drug
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
US4342870A (en) * 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
US4337261A (en) * 1980-07-28 1982-06-29 Hoechst-Roussel Pharmaceuticals Inc. (1,2-Benzisoxazol)phenoxyacetic acids as diuretics
US4443451A (en) * 1981-07-15 1984-04-17 Janssen Pharmaceutica N.V. Bicyclic pyrimidin-5-one derivatives
AU549582B2 (en) * 1981-07-30 1986-01-30 Dow Corning Corporation Silicone elastomer based roofing system
US4352811A (en) * 1981-11-12 1982-10-05 Hoechst-Roussel Pharmaceuticals Inc. 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
US4529727A (en) * 1982-04-21 1985-07-16 Janssen Pharmaceutical, N.V. Pyrimido[2,1-b][1,3]-thiazines
US4485107A (en) * 1982-11-01 1984-11-27 Janssen Pharmaceutica N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones
US4458076A (en) * 1983-05-31 1984-07-03 Hoechst-Roussel Pharmaceuticals 3-(4-Piperidinyl)-1,2-benzisothiazoles
EP0144101B1 (en) * 1983-11-30 1991-02-06 Janssen Pharmaceutica N.V. Bicyclic heterocyclyl containing n-(bicyclic heterocyclyl)-4-piperidinamines
PH23995A (en) * 1984-01-09 1990-02-09 Janssen Pharmaceutica Nv 4((bicycle heterocyclyl)-methyl and hetero)piperidines
US4665075A (en) * 1984-12-05 1987-05-12 Janssen Pharmaceutica N.V. Derivatives of hydroxy- or amino-substituted (piperidinylalkyl)quinazolines
US4689330A (en) * 1985-04-15 1987-08-25 Janssen Pharmaceutica N.V. Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol- and thiazolamines
NL8601494A (nl) * 1985-06-22 1987-01-16 Sandoz Ag Thiazolen, hun bereiding en farmaceutische preparaten die ze bevatten.

Also Published As

Publication number Publication date
LU88576I2 (fr) 1995-03-21
CA1256867A (en) 1989-07-04
CY1801A (en) 1995-02-17
NL940006I2 (nl) 1999-09-01
DK168537B1 (da) 1994-04-18
AU579232B2 (en) 1988-11-17
CN1022566C (zh) 1993-10-27
JPH0613511B2 (ja) 1994-02-23
SG119294G (en) 1995-03-17
EP0196132A2 (en) 1986-10-01
US4804663A (en) 1989-02-14
EP0196132A3 (en) 1988-01-20
DK143986D0 (da) 1986-03-26
JPS61221186A (ja) 1986-10-01
CN86101906A (zh) 1986-10-01
HK108794A (en) 1994-10-14
SU1468419A3 (ru) 1989-03-23
IE860801L (en) 1986-09-27
BG60432B2 (bg) 1995-03-31
EP0196132B1 (en) 1992-08-12
DK143986A (da) 1986-09-28
IE58388B1 (en) 1993-09-08
AU5529786A (en) 1986-10-02

Similar Documents

Publication Publication Date Title
NL940006I1 (nl) 1,2-Benzisoxyzol-3-yl- en 1,2-benzisothiazol-3-yl-derivaten
DK119285D0 (da) Benzothiazol- og benzothiophenderivater
DE3671434D1 (de) Phenylalaninderivate und proteinaseinhibitor.
DK254488D0 (da) Azaindol- og indolizinderivater
DK615186D0 (da) Substituerede 5,6-dialkoxyquinazolinderivater
DE3684549D1 (de) Carboxamidderivate.
DK139286A (da) Inden- og naphthalenderivater
DK109186D0 (da) Dihydropyridazinonderivater
DK470886D0 (da) Oxazol- og isoxazolderivater
DE3680771D1 (de) Isoxazolopyridophenoxazin- und isothiazolopyridophenoxazinderivate.
NO854968L (no) Alkosymetyleter- og alkoksymetylesterderivater.
DK491786A (da) Dichloranilinderivater
DK104186A (da) 2,3,4-triacylhexoser og blandinger deraf
DK556386D0 (da) Quinilinderivater
DE3680775D1 (de) Isoxazolopyridobenzoxazin- und isothiazolopyridobenzoxazinderivate.
DK77186D0 (da) 1,4,6-tri-0-acylerede hexosederivater samt deres fremstilling og anvendelse
DK212786A (da) 1,3-dioxanethere
DK303886A (da) Secocanthinderivater
DE3662889D1 (de) Tetrahydrofurancarboxylic-acid derivatives
KR880700821A (ko) 데--데옥시테이코플라닌 유도체
LV5778A4 (lv) 1,2-Benzizoksazol-3-il- un 1,2-benzizotiazol-3-il-atvasinajumi
IT1190646B (it) 2,4-dicloro-5-nitro-tiazolo
DK109086A (da) 2-aminopyrimidinonderivater
DE3662890D1 (de) Furobenzisoxazole derivatives
NO892248L (no) Alkoksymetyleter- og alkoksymetylesterderivater.